Profile of systemic antifungal use in an Intensive Care Unit of a high complexity hospital

• Autor(a) principal: Moraes, Sabrina Santarém de
• Data de Publicação: 2022
• Outros Autores: Badin, Rebeka Caribé
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Research, Society and Development
• Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/28385
• topic: Antifungal Agent; Echinocandins; Health teaching; Intensive care unit.; Agentes antifúngicos; Equinocandinas; Ensenãnza en salud; Unidad de cuidados intensivos.; Agentes Antifúngicos; Equinocandinas; Ensino de saúde; Unidade de terapia intensiva.

In recent decades, there has been a considerable increase in the incidence and diversity of fungal infection. As a result, 1.5 million patients die annually in hospitals due to invasive fungal infections. This article aims to evaluate the profile of antifungal use in adults in the ICU of a University Hospital. This is a cross-sectional and retrospective study carried out in the ICU of the Getúlio Vargas University Hospital, located in the State of Amazonas, belonging to the Unified Health System (SUS), from March/2019 to May/2021. A total of 100 patients were included in the study, the mean age was 53.86 ± 16.11 years, and the mean length of stay in the hospital was 41.08 ± 29.09 days. The main indication for antifungal therapy was the treatment of candida infection, followed by respiratory tract infections. Among the antifungal treatments prescribed, micafungin stood out. When analyzing consumption by DDD, it was observed that there had been a gradual increase in the use of micafungin in recent years. That way, it is concluded that the complications resulting from the infection by COVID-19 changed the profile of use of this important class. In this context, the CCIH is one of pillars for establishing adequate criteria in the choice of antifungal therapy.